

ACTIVITIES REPORT FOR THE QUARTER ENDED 30 JUNE 2026

HIGHLIGHTS

- Final stage discussions with Triple-S in Puerto Rico, including executive engagement and evaluation of enterprise imaging infrastructure
- Continued success from the PNS Contract and commencement of negotiations for a renewal and expansion of the PNS Contract
- Miami-Dade County Public Schools (M-DCPS) deployment preparations completed, with the first student cohort scheduled to commence in September 2026
- Successfully maintained ISO 27001, HIPAA and SOC 2 Type II compliance requirements and continued progress toward HITRUST certification
- Progressed national phase patent filings across multiple jurisdictions following favourable patentability outcomes for the Company's Medical File Transfer Protocol (MFTP) technology
- Strong cash position of \$10.1 million at quarter end provides funding runway of close to two years to execute the Company's expanding U.S. commercial pipeline.

The June 2026 Quarter marked a period of continued commercial advancement and operational strengthening for Singular Health Group Limited (ASX: SHG) ("Singular Health" or "the Company"), with significant progress achieved across healthcare payer engagement, government initiatives, educational deployments, product development, regulatory compliance and organisational capability.

Singular Health Managing Director & CEO, Denning Chong stated:

"We spent the June Quarter growing our product range and our sales pipeline in the United States. I am excited to see the level of strong engagement with various health plans and diagnostic centres and strategic business partners, which we are seeking to convert into commercial contracts over the coming quarters. We are in an excellent position to now focus on growth."

Singular Health remains focused on converting opportunities into commercial outcomes, including:

- (a) a commercial contract with Triple-S;*
- (b) advancing the substantive Florida Statewide Imaging Repository project opportunity;*
- (c) expanding educational deployments;*
- (d) renewal and expansion of the PNS contract; and*
- (e) continuing to build the enterprise infrastructure capabilities required to support healthcare systems, providers and payers at scale."*

These opportunities further reinforce the Company's strategy of delivering large, scalable, interoperable imaging infrastructure solutions that reduce duplication, improve access to medical imaging and support better healthcare outcomes.

PNS Contract update

Singular Health continues to strengthen its strategic relationship with Provider Network Solutions ("PNS"), one of the Company's key commercial partners in the United States. Following the successful deployment of an additional 500 3DICOM MD® licences during the previous quarter, the platform is now operating across 750 Primary Care Provider (PCP) licences throughout the PNS network.

During the reporting period, Singular Health received the contracted licence payment of US\$500,000 from PNS in accordance with the Binding Enterprise Agreement (refer ASX announcement dated 19 June 2025).

PNS confirms that the solution continues to exceed expectations, with early data demonstrating strong commercial outcomes, continued improvements in care coordination and reductions in unnecessary image utilisation across participating providers.

Given the success PNS has commenced engagement with Singular Health to renew and expand the number of licences contracted, which are due to expire at the end of Q3 CY2026.

PNS confirms its desire to expand deployment across the broader PNS network and is mapping a strategic large-scale rollout strategy.

Beyond the existing deployment, Singular Health and PNS continue to actively and jointly pursue additional commercial opportunities through PNS's affiliate organisations, joint venture partners and other U.S. healthcare payers.

These activities complement the Company's broader commercial strategy and are progressing alongside advanced discussions with prospective health plan customers, further strengthening the Company's U.S. growth pipeline.

Life Radiology Pilot Continues to Expand

The Life Radiology deployment in Florida continues to demonstrate strong operational performance and patient adoption.

The pilot utilises 3DICOM™ Gateway and 3DICOM™ Patient to provide patients and providers with secure, immediate access to medical imaging without reliance on compact disks (CDs) and physical media.

As at the reporting date, the pilot had enrolled more than 230 patients and completed approximately fifteen weeks of operation. Management continues to monitor patient engagement, utilisation metrics and workflow outcomes to support future commercial expansion opportunities.

The continued success of the deployment reinforces the value proposition of the 3DICOM™ ecosystem in improving patient access to imaging while reducing administrative burden for healthcare providers.

M-DCPS Educational Deployment

During the Quarter, Singular Health continued implementation activities associated with its deployment of 3DICOM™ EDU within Miami-Dade County Public Schools (M-DCPS), the third largest public school district in the United States.

Multiple stakeholder workshops were completed, administrative users were provisioned and implementation planning activities progressed in preparation for student onboarding.

The first student cohort is scheduled to commence activities in September 2026. The deployment will utilise 3DICOM™ EDU to support anatomy education and healthcare training programs across participating departments.

The Company views this deployment as an important opportunity to further validate its educational technology platform and support broader adoption within healthcare education environments. The Company believes that upon success of this implementation, the opportunity represents a scalable and replicable model throughout Florida, and across the United States.

Florida State Imaging Repository Project

Singular Health continues its involvement in the Florida Statewide Imaging Repository initiative, which includes a requested project funding amount to the State of Florida which is anticipated to be substantive to the Company.

This project proposes the creation of a statewide imaging repository capable of receiving, storing and analysing medical imaging data and associated radiology reports generated by Medicaid-enrolled providers throughout Florida.

Management continues to view this initiative as a transformational opportunity capable of demonstrating the value of interoperable imaging infrastructure at statewide scale while generating meaningful commercial outcomes.

Singular Health expects an outcome regarding the requested project funding in Q3 CY2026.

Triple-S Engagement And Health Plan Opportunities

Singular Health continues to progress final stage discussions with Triple-S, one of Puerto Rico's leading health plans, regarding deployment of the 3DICON™ platform, including 3DICON MD®, 3DICON Patient, 3DICON Gateway, AI-in-the-Cloud (AIC), and a Utilisation Management (UM) / Radiology Benefit Management (RBM) workflow solutions.

During the Quarter, discussions progressed with Triple-S's newly appointed Chief Executive Officer and senior leadership team, with strategic meetings held to finalise adoption of the proposed solution and its ability to improve healthcare coordination, reduce duplicate imaging and strengthen utilisation management outcomes.

Discussions also continue regarding potential early enrolment of three Triple-S-owned centres within the existing PNS pilot program.

The Company views the Triple-S engagement as an important strategic opportunity within the healthcare payer market and remains focused on progressing discussions toward a commercial outcome.

Additionally, via the introduction by PNS, Singular Health strengthens its commercial pipeline, having commenced positive engagement with the biggest health plan in Puerto Rico, other health plans in mainland USA, and various large diagnostic centres in Florida. The Company views that the ever-growing pipeline represents an ongoing flow of large scale opportunities over the following year.

Product Development and Technology Advancement

Development activities during the Quarter remained closely aligned with active commercial opportunities and the Company's long-term strategy of building an interoperable healthcare imaging infrastructure platform.

The Company continued development of a comprehensive end-to-end imaging request and approval workflow supporting Primary Care Providers, Utilisation Management teams and Radiology Benefit Managers. The solution extends existing Gateway Search and Audit capabilities and introduces structured workflows designed to assess prior imaging availability, evaluate imaging appropriateness and support evidence-based decision making before new imaging studies are ordered.

Development also continued on modular clinical connectors supporting integration with Radiology Information Systems (RIS), Laboratory Information Systems (LIS) and Electronic Health Record (EHR) platforms. These capabilities further strengthen the reach and interoperability of the 3DICON™ ecosystem and enhance the Company's ability to operate within complex healthcare environments.

Finally, the Company continues to develop its framework for integration and use of AI models for its marketplace. Upon completion, this represents large scale commercial opportunities utilising AI models to create efficiencies for health plans, and/or utilising and commercialising the use of images and data in the AI sector.

In parallel, the Company is building a dedicated learning and onboarding platform, providing enterprise customers with on-demand access to educational content, implementation resources, product documentation and training materials. The platform is expected to improve onboarding efficiency and support customer success outcomes as deployments continue to scale.

Quality, Regulatory and Cybersecurity

Maintaining a strong governance, compliance and information security framework remains a strategic priority for Singular Health.

During the Quarter, the Company successfully maintained compliance with:

- ISO 27001
- HIPAA
- SOC 2 Type II

These achievements demonstrate the maturity of the Company's information security controls and support customer confidence in the deployment of Singular Health's enterprise healthcare solutions.

The Company also continued implementation activities toward HITRUST certification, further strengthening its ability to engage with large healthcare organisations, payers and government agencies across the United States.

Intellectual Property

Singular Health continued to strengthen and protect its intellectual property portfolio during the Quarter.

National phase patent filings progressed across Australia, the United States, Europe, Canada, Brazil, Mexico, Colombia, Indonesia and Vietnam following receipt of a favourable International Preliminary Report on Patentability from the World Intellectual Property Organization (WIPO).

The report confirmed that all examined claims relating to the Company's Medical File Transfer Protocol (MFTP) technology were both novel and inventive, significantly strengthening the Company's global intellectual property position and supporting future commercialisation opportunities. The report does not constitute the grant of a patent, and each application remains subject to examination and approval by the relevant national or regional patent office.

Industry Engagement & Strategic Partnerships

During the Quarter, Singular Health's Chief Commercial Officer attended the Health AI Summit in Anaheim, California, held in May 2026 and the Society for Imaging Informatics in Medicine (SIIM) Annual Meeting held in June 2026.

Additionally, a new partnership between Singular Health and Talk2View led to the submission of an application under the Cooperative Research Centres Projects (CRC-P) program which includes significant funding grants. The application remains subject to assessment, and there is no certainty that funding will be awarded. Talk2View has developed an AI-assisted visual communication platform that enables users to interact with complex visual content through natural language, making medical imaging and other technical information easier to understand, navigate and explain.

The proposed project seeks to integrate Talk2View's AI software development kit (SDK) into Singular's commercial 3DICOM platform to create more intuitive and interactive imaging experiences for clinicians, educators and patients, while validating the technical, regulatory and commercial pathways for advanced healthcare visualisation technologies. The initiative aligns strongly with the Company's broader healthcare infrastructure strategy and has the potential to expand platform capability, enhance user engagement and strengthen strategic partnerships.

Business Activities Expenditure

During the Quarter, Singular Health continued to invest in the execution of its commercial strategy, product development and organisational capability while maintaining disciplined financial management.

Customer receipts for the Quarter totalled **\$721,000**, reflecting the receipt of the contracted US\$500,000 license payment from Provider Network Solutions (PNS) under the Binding Enterprise Agreement and representing a significant increase compared to the previous quarter. Interest income of **\$132,000** was also received during the period, reflecting the Company's continued strong cash position.

In accordance with ASX Listing Rule 4.7C.1, direct operating activities expenditure for the Quarter was **\$1,710,000**, comprising:

- research and development expenses of **\$320,000**;
- product manufacturing and operating costs of **\$167,000**;
- advertising, marketing and investor relations costs of **\$70,000**;
- staff costs of **\$841,000**; and
- administration and corporate costs of **\$312,000**.

These remain in line with the Company's budgeted forecasts for the Quarter.

The increase in operating expenditure compared with the previous quarter primarily reflects continued growth, and investment in product development, expansion of engineering capability through the appointment of key leadership personnel, commercialisation activities supporting the Company's growing U.S. pipeline, and ongoing implementation of enterprise customer deployments.

These investments remain aligned with the Company's strategy of positioning the 3DICOM™ platform for scalable commercial growth.

During the Quarter, the Company received approval and confirmation of its R&D Rebate in the amount of **\$471,540**. The rebate is expected to be received by the Company in Q3 CY2026.

The Company also received **\$795,000** from the exercise of unlisted options and **\$127,000** from the disposal of non-core assets, further strengthening the Company's balance sheet and liquidity position.

In accordance with ASX Listing Rule 4.7C.3, payments to related parties of the entity and their associates during the Quarter amounted to **\$117,000**, comprising Managing Director remuneration and Non-Executive Director fees.

The Company had a strong cash position of \$10.069m at the June quarter-end.

The Company remains well capitalised and has a strong funding runway of close to two years to execute its strategic objectives, progress key commercial opportunities to revenue, and continue investment in product development, regulatory compliance and market expansion.

Activities Subsequent to Period End

Subsequent to the end of the Quarter, Singular Health executed a Memorandum of Understanding with Stellae Health, a Florida-based provider organisation within the Provider Network Solutions (PNS) network, to commence a pilot deployment of the 3DICOM™ platform across participating primary care practices. The MOU is non-binding, does not presently generate revenue and is intended to establish the framework for a pilot deployment.

The pilot will evaluate the ability of 3DICOM™ to improve access to external medical imaging, streamline imaging workflows, increase visibility of prior imaging studies and reduce unnecessary repeat imaging.

The initiative represents a further expansion of the Company's relationship with the broader PNS ecosystem and demonstrates increasing market adoption of the 3DICOM™ platform within U.S. healthcare networks.

Outlook

The Company expects continued progress across its U.S. commercial opportunities during the coming quarter.

Management remains focused on continuing successful use of 3DICOM™ platform by PNS, continuing and expanding current pilot deployments, finalising discussions with Triple-S toward a commercial contract, supporting the successful launch of the Miami-Dade County Public Schools deployment, and progressing the Florida Statewide Imaging Repository project through the relevant approval stages.

The Company also expects ongoing advancement of enterprise healthcare workflow capabilities, interoperability infrastructure and educational technology initiatives, further strengthening the commercial value proposition of the 3DICOM™ ecosystem.

Singular Health remains confident that its growing pipeline of healthcare payer, provider, education and government opportunities provides a strong foundation for long-term large scale contracts.

Authorised for ASX release by the Board of Directors.

Ends

For further information contact:

Denning Chong
Managing Director & CEO
support@singular.health
1300 167 795

Paul Berson
Investor Relations
paul@corporatestorytime.com
+61 421 647 445

About Singular Health

Singular Health is a Western Australian, ASX-listed (ASX: SHG) medical technology company on a mission to create a seamless and integrated healthcare ecosystem where the full value of medical imaging records is unlocked, enabling universal access and promoting interoperability to maximise patient outcomes.

Singular Health's 3DICOM™ software solutions empower patients and practitioners to better visualise, communicate, and understand medical imaging data. 3DICOM™ MD® is cleared for diagnostic use in the United States.

To learn more, visit <https://singular.health> and <https://investors.singular.health/>

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Singular Health Group Limited

ABN

58 639 242 765

Quarter ended ("current quarter")

30 June 2026

	Current quarter \$A'000	Year to date (12 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	721	796
1.2 Payments for		
(a) research and development	(320)	(985)
(b) product manufacturing and operating costs	(167)	(359)
(c) advertising, marketing and investor relations	(70)	(501)
(d) leased assets	-	-
(e) staff costs	(841)	(3,179)
(f) administration and corporate costs	(312)	(1,437)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	132	387
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	-
1.8 Other	-	-
1.9 Net cash from / (used in) operating activities	(857)	(5,278)
2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	(17)	(131)
(d) investments	-	-
(e) intellectual property	-	-

		Current quarter \$A'000	Year to date (12 months) \$A'000
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	127	168
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other	-	-
2.6	Net cash from / (used in) investing activities	110	27
3.	Cash flows from financing activities		
3.1	Proceeds from issues/unissued of equity securities (excluding convertible debt securities)	-	150
3.2	Proceeds from issue of convertible notes	-	-
3.3	Proceeds from exercise of share options	795	1,545
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	(52)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other – lease payments	(5)	(9)
3.10	Net cash from / (used in) financing activities	791	1,634
4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	10,014	13,679
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(857)	(5,279)

		Current quarter \$A'000	Year to date (12 months) \$A'000
4.3	Net cash from / (used in) investing activities (item 2.6 above)	110	27
4.4	Net cash from / (used in) financing activities (item 3.10 above)	791	1,634
4.5	Effect of movement in exchange rates on cash held	11	8
4.6	Cash and cash equivalents at end of period	10,069	10,069

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	1,764	1,010
5.2	Call deposits	8,300	9,000
5.3	Bank overdrafts	-	-
5.4	Other (Bank Guarantee)	5	5
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	10,069	10,015

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	117
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
6.3	Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2	
	- Aggregate amount salary paid to Managing Director (\$70k), and Non-Executive Director fees of (\$47k).	

7.	Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i> <i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	Total financing facilities	-	-
7.5	Unused financing facilities available at quarter end		-
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		
	-		

8.	Estimated cash available for future operating activities	\$A'000
8.1	Net cash from / (used in) operating activities (item 1.9)	(857)
8.2	Cash and cash equivalents at quarter end (item 4.6)	-
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.4 + item 8.5)	10,069
8.5	Estimated quarters of funding available (item 8.6 divided by item 8.3)	11.75
	<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
	8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
	Answer: N/A	
	8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
	Answer: N/A	
	8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
	Answer: N/A	
	<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

31 July 2026

Date:

The Board of Directors

Authorised by:
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.